Xeris Biopharma Holdings Inc (STU:2B30)
€ 3.302 0.14 (4.43%) Market Cap: 490.65 Mil Enterprise Value: 684.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q4 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript

Mar 08, 2023 / 01:30PM GMT
Release Date Price: €1.42 (+5.97%)
Operator

Hello, and welcome to the Xeris Biopharma Fourth Quarter and Year-end 2022 Conference Call. My name is Alex. I'll be coordinating the call today. (Operator Instructions)

I'll now hand over to your host, Allison Wey, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.

Allison Wey
Xeris Biopharma Holdings, Inc. - SVP of IR & Corporate Communications

Thank you, Alex. Good morning, and welcome to Xeris' Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast. A press release with the company's financial results was issued earlier this morning and can be found on our website.

We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, CFO. Paul will provide opening remarks. Steve will provide details on our financial results. And after a few closing remarks by Paul, we will open the call for Q&A.

Before we begin, I would like to remind you that this call will contain forward-looking statements, which may include, but are not limited to, statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot